For research use only. Not for therapeutic Use.
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury[1][2].<br>Daltroban (BM-13505) (1 mg/kg; i.v.; per hour) exerts protective effect in reperfusion injury following acute myocardial ischemia in cats[2].
In comparison with vehicle (physiological saline)-treated cats, Daltroban (20 mg/kg per hour i.v.) reduces the ischaemia-induced rise in the ST segment and prevented the development of a Q-wave in the ECG during reperfusion. Daltroban protects the myocardium from ischaemic injury and that this effect involves prevention of ischaemia-induced leukocytosis[3].
| Catalog Number | I017416 |
| CAS Number | 79094-20-5 |
| Molecular Formula | C₁₆H₁₆ClNO₄S |
| Purity | ≥95% |
| Target | Prostaglandin Receptor |
| Reference | [1]. Miki I, et al. Differences in activities of thromboxane A2 receptor antagonists in smooth muscle cells. Eur J Pharmacol. 1992 Oct 1;227(2):199-204.<br>[2]. Thiemermann C, et al. The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis. Eur J Pharmacol. 1988 Oct 11;155(1-2):57-67.<br>[3]. Bhat AM, et al. Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats. Am Heart J. 1989 Apr;117(4):799-803. |
